Currently Viewing:
Newsroom
Currently Reading
NICE Endorses Funding for Ibrutinib in Patients With CLL
January 27, 2017 – AJMC Staff
First Trial With Universal CAR-T Treatment in Pediatric Leukemia Reports Success
January 26, 2017 – Surabhi Dangi-Garimella, PhD
New Target for Treating Glioblastoma May Increase Survival Time
January 26, 2017 – AJMC Staff
Study Doubts Impact of Pre-ACA Medicaid Expansion on Access to Cancer Surgery
January 25, 2017 – Surabhi Dangi-Garimella, PhD
JAMA Study Discovers Regional Trends in Cancer-Related Mortality
January 25, 2017 – Surabhi Dangi-Garimella, PhD
Study Reveals Why Immuno-Oncology Treatments Are Effective in Only a Minority of Patients
January 24, 2017 – Surabhi Dangi-Garimella, PhD
Two Discoveries With Cervical Cancer: Novel Regulatory Genes and the True Mortality Rate
January 23, 2017 – Surabhi Dangi-Garimella, PhD
What We're Reading: Experts Rush to Understand Trump's Executive Order
January 23, 2017 – AJMC Staff
Dr Richard Pazdur Confirmed Director of FDA's Oncology Center of Excellence
January 20, 2017 – Surabhi Dangi-Garimella, PhD

NICE Endorses Funding for Ibrutinib in Patients With CLL

AJMC Staff
Patients who have had at least 1 prior therapy or carry a 17p deletion or TP53 mutation are now eligible to be treated with ibrutinib (Imbruvica) in the United Kingdom.
Patients who have had at least 1 prior therapy or carry a 17p deletion or TP53 mutation are now eligible to be treated with the Burton’s tyrosine kinase inhibitor ibrutinib (Imbruvica) developed by Janssen, according to the National Institutes of Health and Care Excellence (NICE), which is the agency that monitors funding for healthcare in England and Wales.

In early 2016, Janssen UK received news that NICE had rejected funding for ibrutinib, which was, at the time, being funded through UK’s Cancer Drug Fund. NICE had doubts about whether the drug—which cost £55,954.50 for a year’s course—would be cost effective. Mark Hicken, managing director of Janssen UK, had said then that the company was negotiating with NICE to demonstrate cost effectiveness and to ensure patient’s continued to have access to the drug.

Results from the RESONATE-2 trial could have swayed the decision in favor of the drug. At the 2016 annual meeting of the American Society of Hematology, Paul Barr, MD, assistant professor of medicine at the University of Rochester Wilmot Cancer Institute, reported impressive results from the trial. In a population of older treatment-naïve patients, the 24-month overall survival was 95% in the ibrutinib arm, compared with 84% for the comparator arm. Hematological functions, too, were significantly improved in patients treated with ibrutinib.

The company is now waiting to see whether NICE also clears ibrutinib for treating patients with mantle cell lymphoma and Waldenström's macroglobulinemia.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up